Lupine Partners with Chinese Fancoo Pharma in Generic Medicine, Health News, ET HealthWorld

Mumbai: The pharmaceutical company Lupine Limited announced on Wednesday that it had entered into a first partnership with the Chinese Shenzhen Foncoo Pharmaceutical Co. Ltd. This partnership agreement with Shenzhen Foncoo by Lupin consists of selling generic drugs to China.

Discussing the partnership, Dr. Fabrice Egros, President – Growth Markets, Lupine said, “Lupin continues to invest in key growth markets. With China’s growing commitment to affordable and accessible healthcare, Lupine is committed to meeting the health needs of the Chinese people by providing high quality generic and complex generic products. We are very happy with our partnership with Foncoo.”

The company will continue to explore other partnership opportunities in China to leverage our global portfolio, including complex generics and specialty drugs, Egros said.

Commenting on the partnership, Peng Yan, Managing Director of Foncoo, said, “Foncoo’s successful experiences in importing, registering and marketing generic formulations and Lupine’s strong ability to manufacture high-quality drugs make them perfectly compatible with each other and our collaboration will most likely have a bright future impact. We expect the successful launch of our first product in China to be quick and smooth. We will also continue to explore other opportunities to work with Lupin to increasingly deliver complex, high-value medicines to Chinese physicians and patients.

Lupine develops and markets a wide range of branded and generic formulations, biotechnology products and APIs in more than 100 markets worldwide.


About Author

Comments are closed.